DDInter583 DDInter927
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Donepezil {u} (Compound) resembles {v} (Compound) Doxazosin
Donepezil {u} (Compound) resembles {v} (Compound) Moexipril
Donepezil {u} (Compound) treats {v} (Disease) Alzheimer's disease
Donepezil {u} (Compound) binds {v} (Gene) CYP2D6
Donepezil {u} (Compound) upregulates {v} (Gene) MAPKAPK5
Donepezil {u} (Compound) downregulates {v} (Gene) CCNB2
Donepezil {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cobicistat
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zafirlukast
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Donepezil (Compound) resembles Doxazosin (Compound)
Donepezil (Compound) resembles Moexipril (Compound)
Donepezil (Compound) treats Alzheimer's disease (Disease)
Donepezil (Compound) binds CYP2D6 (Gene)
Donepezil (Compound) upregulates MAPKAPK5 (Gene)
Donepezil (Compound) downregulates CCNB2 (Gene)
Donepezil (Compound) causes Abdominal pain upper (Side Effect)
Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Donepezil may cause a minor interaction that can limit clinical effects when taken with Zafirlukast
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin